Organizations
Conferences
Info & Opinion
August 29, 2008
A biostatician with deep NIH and FDA ties talks about general guidelines for changing primary end points. Plus, the M-word.
Not long ago, on a bleak winter morning when the U.S. Congress and the New York governor and the Connecticut attorney general and the second most important medical journal were trashing the industry, we banged out an email to Scott…
No articles available